Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cardiology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cardiology Other
    The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials - (BMJ)
    FDA Approves Dronedarone for Atrial Fibrillation or Atrial Flutter - (DGNews)
    Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease - (JAMA)
    Novel and conventional biomarkers for prediction of incident cardiovascular events in the community - (JAMA)
    Kidney function and risk of cardiovascular disease and mortality in women: a prospective cohort study - (BMJ)

    News archive

     Recent webcasts/CME - Cardiology Other
    • State of the Science in Managing the Treatment-Experienced Patient With HIV
    • What's New in Managing Treatment-Experienced Patients With HIV?
    • Applying Data to Practice: Case Vignettes
    • Rheumatoid Arthritis: The Heart of the Matter Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis
      Supraventricular Tachycardia in Children and Adolescents

      Webcasts/CME archive

       Recent cases - Cardiology Other
        Cardiogenic Shock Caused by Disulfiram
        Congenital Atresia of the Left Main Coronary Artery Associated With Patent Ductus Arteriosus and Aortic Regurgitation
        Pleural Effusion and Pulmonary Hypertension in a Patient With Parkinson Disease Treated With Cabergoline
        A Well-Circumscribed Density Along the Right Heart Border
        A Case of Massive Pulmonary Embolism with ST Elevation in Leads V1-4

        Cases archive
          




        my personal edition > cardiology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        ACE-Inhibitors Improve Outcomes in Coronary Artery Disease: Presented at AHA

        By Jill Stein

        DALLAS, TX -- November 15, 2005 -- Data from a large meta-analysis support a beneficial effect of treatment with angiotensin-converting-enzyme (ACE)-inhibitors added to conventional therapy on outcome in patients with coronary artery disease (CAD) and preserved left ventricular (LV) systolic function.

        The findings were presented here on November 14th at the American Heart Association's Scientific Sessions 2005 (AHA).

        Mouaz Al-Mallah, MD, Chief Cardiology Fellow, Henry Ford Hospital, Detroit, Michigan, United States, and associates reviewed data in 33,959 patients with stable CAD and preserved LV systolic function who had been randomized to ACE-inhibitor treatment or placebo.

        Participants were drawn from seven randomized, placebo-controlled trials. A total of 17,000 received an ACE inhibitor and 16,959 received placebo.

        "The evidence for routine administration of ACE-inhibitors has been contradictory in patients with coronary artery disease with preserved LV systolic function," Dr. Al-Mallah observed. "While two large trials demonstrated a decrease in cardiovascular death and myocardial infarction, no such benefit was found in another large trial and in a few smaller trials."

        The present investigation showed that ACE-inhibitor treatment produced a 3.9 mm Hg mean decrease in systolic blood pressure and a 1.8 mm Hg mean decrease in diastolic pressure.

        ACE-inhibitor treatment was also associated with a reduction in cardiovascular mortality (RR=0.83, P = .006), non-fatal MI (RR=0.82, P = .001), all-cause mortality (RR=0.87, P = .0002), and revascularization (RR=0.92, P = .04).

        "Our systematic review has several strengths," Dr. Al-Mallah noted. "For example, it helps answer the general question of the beneficial effects of ACE-inhibition in patients with coronary artery disease and preserved LV function with different treatment regimens," he said.


        [Presentation title: Angiotensin-Converting-Enzyme Inhibitors Improve Outcomes in Patients with Coronary Artery Disease: a Meta-Analysis of Randomized Controlled Trials. Abstract 2153]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send